Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06152653 · ClinicalTrials.gov registry record · Phase 4
The Effects of Positive Airway Pressure on the Mucolytic Effects of NAC (TEAM)
A Phase 4 study of Asthma and COPD, sponsored by University of California, San Francisco.
- Recruiting
- Registry status
- Phase 4
- Development phase
- 40
- Enrollment target
- 1
- Study location
NCT06152653: Recruiting Phase 4 study of Asthma and COPD, sponsored by University of California, San Francisco.
NCT06152653 is a Phase 4 study of Asthma and COPD that is actively recruiting participants, run by University of California, San Francisco. The registered enrollment target is 40 participants, below the 1,563-participant average among 374 other Asthma trials with a reported enrollment target (97% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06152653, a Phase 4 study of Asthma and COPD, is actively recruiting participants, sponsored by University of California, San Francisco.
- RECRUITING
- Registry status
- Phase 4
- Development phase
- 40 participants
- Enrollment target
- 1
- Study location
Study Summary
The goal of this clinical trial is to determine if positive pressure during inspiration will improve penetration of aerosolized N-Acetylcysteine (NAC) into airway mucus plugs in the lungs of patients with asthma or Chronic Obstructive Pulmonary Disease (COPD). The main questions it aims to answer are: * Does delivery of aerosolized NAC with positive inspiratory pressure have a greater effect on mucus plug burden in the lungs than delivery of NAC without positive pressure. * Does delivery of aerosolized NAC with positive inspiratory pressure have a greater effect on lung function than delivery of NAC without positive pressure. Participants will be assigned (in a single blind design) to the NAC via jet nebulizer group or the NAC via AeroEclipse-VersaPAP nebulizer group. Participants will each complete 5 treatment visits over the course of 30 days. Each treatment visit will consist of two treatments of a 10% NAC (3 mL) and 2.5 mg albuterol (0.5mL) inhalation solution separated by 4 hours, via the nebulization method specific to their group.
Primary Outcome
The primary outcome is the % change in mucus plug score from 1 week before treatment to 1 week post treatment.
Interventions
- DRUG n-acetylcystine (NAC)+ albuterol
- DEVICE AeroEclipse-VersaPAP System
Study Locations (1)
California
- UCSF Airway Clinical Research Center - San Francisco
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 40 participants |
| Start Date | 2024-04-09 |
| Est. Completion | 2027-04 |
| Phase | Phase 4 |
What NCT06152653 shows while recruiting
NCT06152653 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 40 participants, a relatively small participant target, below the 1,563-participant average among 374 other Asthma trials with a reported enrollment target (97% lower).
The record links to 2 conditions, with Asthma appearing as the primary indexed condition, and to 2 interventions - of which n-acetylcystine (NAC)+ albuterol is the first listed.
NCT06152653 reports a single indexed study location in California.
Frequently Asked Questions
What is clinical trial NCT06152653 about?
NCT06152653 is a clinical study titled "The Effects of Positive Airway Pressure on the Mucolytic Effects of NAC (TEAM)". The goal of this clinical trial is to determine if positive pressure during inspiration will improve penetration of aerosolized N-Acetylcysteine (NAC) into airway mucus plugs in the lungs of patients with asthma or Chronic Obstructive Pulmonary Disease (COPD). The main questions it aims to answer a...
What is the current status of trial NCT06152653?
This trial is currently recruiting. It is a Phase 4 study. The enrollment target is 40 participants. The study started on 2024-04-09. Estimated completion is 2027-04.
What conditions does trial NCT06152653 study?
This clinical trial studies the following conditions: Asthma, COPD.
What interventions are being tested in trial NCT06152653?
The interventions under investigation include: n-acetylcystine (NAC)+ albuterol (DRUG), AeroEclipse-VersaPAP System (DEVICE).
Who is sponsoring clinical trial NCT06152653?
This trial is sponsored by University of California, San Francisco, which has 1,713 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06152653 being conducted?
This trial has 1 study location across California. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Asthma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT06152653's enrollment target sits among peer trials
40 282nd of 374 higher than 91 of 374 other Asthma trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Asthma trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Measuring the Effect of Dupilumab Treatment on Mucociliary Clearance (MCC) in Subjects With Moderate to Severe Asthma
RECRUITING · Phase 4
-
Study Assessing the Long-term Effect of Dupilumab on Prevention of Lung Function Decline in Adult Patients With Uncontrolled Moderate to Severe Asthma
RECRUITING · Phase 4
-
Viral Infection in Asthma (VIA) Study
RECRUITING · Phase 4
-
Mechanism(s) of Airflow Limitation During Exacerbation of Asthma
RECRUITING · Phase 4
-
Efficacy of Dupilumab Added to Medium Dose Inhaled Corticosteroid/Long-acting Beta-agonist (ICS/LABA) in Comparison to ICS Dose Escalation to High Dose ICS/LABA in Adolescent and Adult Patients With Uncontrolled Asthma
RECRUITING · Phase 4
-
Individualizing Treatment for Asthma in Primary Care (Full Study)
RECRUITING · Phase 4
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01306019 · 40 participants · Phase 1
Lentiviral Gene Transfer for Treatment of Children Older Than Two Years of Age With X-Linked Severe Combined Immunodeficiency (XSCID)
- NCT01608152 · 40 participants
Development of a Video Game for the Improvement of Outcomes in Stem Cell Transplant Survivors
- NCT01668082 · 40 participants · NA
An Investigation of Brain Tumor Metabolism in Patients Undergoing Surgical Resection
- NCT02015013 · 40 participants · Phase 2
Hematopoietic Stem Cell Mobilization in Idiopathic CD4 Lymphocytopenia Patients and Healthy Controls for the Study of T Cell Maturation and Trafficking in Murine Models
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI